The clinical course of CML involves not only the dysregulation of tyrosine kinase function, but also manifests as a deep dysfunctional immune response against tumor cells expressing the fusion gene BCR-ABL1. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.